Neoadjuvant chemotherapy has been used for years to treat patients with breast cancer whose primary tumors are too large to allow for breast conservation surgery [1]. Reduction in size of the primary tumor with neoadjuvant chemotherapy has made possible the use of lumpectomies instead of mastectomies in a large fraction of these cases. In the past this was the major objective of neoadjuvant chemotherapy for breast cancer, but more recently the focus has changed and the goals have expanded [2]to include: 1- determination of the chemosensitivity of the tumor so that subsequent chemotherapy can be modified accordingly. 2- to prolong disease free survival . 3- to prolong survival.